ALFA Finder
India's fastest NSE & BSE filing alerts on Telegram, filtered to the stocks you hold
Telegram alerts
alfafinder.com →
ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
15 announcements with these filters
Aarti Drugs disclosed that the US FDA inspected its subsidiary Pinnacle Life Science's Baddi plant on 2-6 November 2026 and issued three Form 483 observations. The company states there is no financial or operational impact.
Q2 FY27 consolidated revenue Rs 826.2 Cr (+27% YoY), EBITDA Rs 137.9 Cr (16.6% margin, +370 bps), PAT Rs 82.8 Cr (+83%). Specialty chemicals nearly doubled; formulations grew 58%.
Aarti Drugs reports Q2 FY27 revenue of ₹828.8 Crore and PAT of ₹82.8 Crore, up 83% YoY. Results reflect record quarterly EBITDA and margin expansion.
Aarti Drugs Ltd reported revenue from operations of ₹826.2 Cr (+26.6% YoY) and net profit of ₹82.8 Cr (+83.2% YoY) for Q2 FY27.
Aarti Drugs Ltd intimated BSE and NSE of a board meeting on November 3, 2026, to consider audited financial results for the quarter and half year ended September 30, 2026. Trading window remains closed until 48 hours after results declaration.
The company submitted its quarterly shareholding pattern as of September 30, 2026, in compliance with SEBI Listing Regulations.
Aarti Drugs has updated its list of authorized personnel for determining materiality of events and making stock exchange disclosures, effective October 1, 2026.
Aarti Drugs Ltd announced the retirement of Director Uday M. Patil and the appointment of new directors, including Adhish P. Patil as the Managing Director.
Aarti Drugs reports Q1 FY27 revenue of ₹704 Cr, up 19% YoY. Management focuses on scaling regulated market sales through high-margin formulations and oncology backward integration.
Aarti Drugs Limited conducted its 41st Annual General Meeting on September 26, 2026, to consider various ordinary and special business resolutions.
Aarti Drugs Ltd has issued a notice for its 41st Annual General Meeting scheduled for September 26, 2026. The agenda includes financial statements and director appointments.
Aarti Drugs has released its Annual Report for FY 2025-26 and notice for its 41st Annual General Meeting scheduled for September 26, 2026.
Aarti Drugs Limited board approved the Performance Stock Option Plan 2026. The plan involves granting up to 8,00,000 stock options to eligible employees, subject to shareholder approval.
Aarti Drugs Ltd scheduled a Board Meeting on August 27, 2026, to consider the 'Aarti Drugs Limited – Performance Stock Option Plan 2026'.
Aarti Drugs Ltd has submitted its quarterly shareholding pattern in compliance with Regulation 31(1)(b) of SEBI (LODR) Regulations for the quarter ended June 30, 2026.